Resistance to targeted therapy in renal-cell carcinoma.

@article{Rini2009ResistanceTT,
  title={Resistance to targeted therapy in renal-cell carcinoma.},
  author={Brian I. Rini and Michael B. Atkins},
  journal={The Lancet. Oncology},
  year={2009},
  volume={10 10},
  pages={992-1000}
}
Therapeutic targeting of integral biological pathways, including those involving vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR), has produced robust clinical effects and revolutionised the treatment of metastatic renal-cell carcinoma (RCC). However, some patients are inherently resistant to these approaches and most, if not all, patients acquire resistance over time. As such, the biological basis for resistance to these targeted therapies and the clinical… CONTINUE READING
Highly Influential
This paper has highly influenced 18 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 223 extracted citations

Similar Papers

Loading similar papers…